

## Press Release

04 January 2022

---

### Cessatech's warrant exercise registered with the Danish Companies Registration Office

**Copenhagen, Denmark, 4 January 2022 – On Thursday, 16 December 2021, the exercise period for Cessatech A/S ("Cessatech" or the "Company") warrants of series TO 1 ended. The warrant exercise has now been registered with the Danish Companies Registration Office (Dk. Erhvervsstyrelsen).**

The total number of registered shares now amounts to 6,112,535 and the share capital amounts to DKK 1,222,507. The conversion from interim shares to common shares will be made on Thursday, 13 January 2022 and the new shares are expected to be in each shareholder's accounts around Monday, 17 January 2022.

**For more information about Cessatech, please contact:**

Jes Trygved, CEO

Phone: +45 9387 2309

E-mail: [jes.trygved@cessatech.com](mailto:jes.trygved@cessatech.com)

[www.cessatech.com](http://www.cessatech.com)

#### **About Cessatech**

Cessatech A/S is a Danish pharmaceutical company committed to developing and commercialising evidence-based and innovative medicines for children for the treatment of paediatric acute pain. Its lead asset (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. The advantages include needle-free administration, being easy to administer, a fast-acting therapeutic effect and being medically approved for children.